All In Biotech

Drug Trial Radar · NCT06108544

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,108

Actual

Start

Nov 6, 2023

Primary completion

Dec 6, 2024

Study completion Nov 7, 2025

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Oct 31, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 69 weeks.

Conditions

  • Plaque Psoriasis

Interventions

  • TAK-279Drug

    Specified drug on specified days.

  • PlaceboDrug

    Specified drug on specified days.

  • ApremilastDrug

    Specified drug on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16 Comparing TAK-279 Against PlaceboTime frame: Baseline, Week 16
  2. Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16 Comparing TAK-279 Against PlaceboTime frame: Baseline, Week 16

Locations

217 sites in 16 countries. Site status is shown where the registry gives one.

  • Total Dermatology

    Birmingham, Alabama

  • Cahaba Dermatology Skin Health Center

    Hoover, Alabama

  • Medical Dermatology Specialists

    Phoenix, Arizona

  • Noble Clinical Research

    Tucson, Arizona

  • Johnson Dermatology Clinic

    Fort Smith, Arkansas

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • Zenith Research, Inc.

    Beverly Hills, California

  • UNISON Clinical Trials (Shahram Jacobs md inc.)

    Encino, California

  • First OC Dermatology Research Inc.

    Fountain Valley, California

  • Long Beach Research Institute, LLC

    Long Beach, California

  • Metropolis Dermatology Downtown LA - Probity - PPDS

    Los Angeles, California

  • Northridge Clinical Trials

    Northridge, California

  • TCR Medical Corporation

    San Diego, California

  • University Clinical Trials

    San Diego, California

  • Dermatology Institute and Skin Care Center

    Santa Monica, California

  • Revival Research Corporation - Florida - ClinEdge - PPDS

    Doral, Florida

  • Florida Academic Centers Research

    Miami, Florida

  • San Marcus Research Clinic Inc

    Miami Lakes, Florida

  • FXM Research Miramar

    Miramar, Florida

  • Lenus Research & Medical Group

    Sweetwater, Florida

  • Advanced Clinical Research Institute (ACRI) - Florida

    Tampa, Florida

  • Olympian Clinical Research - 6331 Memorial Hwy

    Tampa, Florida

  • Divine Dermatology and Aesthetics, LLC

    Atlanta, Georgia

  • Advanced Medical Research, PC

    Atlanta, Georgia

  • Skin Care Physicians of Georgia

    Macon, Georgia

  • NorthShore Medical Group Dermatology - Skokie

    Skokie, Illinois

  • DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location

    Clarksville, Indiana

  • Skin Sciences, PLLC

    Louisville, Kentucky

  • DS Research of Kentucky

    Louisville, Kentucky

  • Dermatology & Advanced Aesthetics

    Lake Charles, Louisiana

  • Lawrence J Green, MD LLC

    Rockville, Maryland

  • Allcutis Research LLC

    Beverly, Massachusetts

  • Beacon Clinical Research LLC

    Brockton, Massachusetts

  • David Fivenson MD Dermatology PLLC

    Ann Arbor, Michigan

  • University of Michigan Hospital - 1500 E Medical Center Dr

    Ann Arbor, Michigan

  • Oakland Hills Dermatology - 3400 Auburn Rd

    Auburn Hills, Michigan

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • Skin Specialists PC

    Omaha, Nebraska

  • Vivida Dermatology - Flamingo Rd - Probity - PPDS

    Las Vegas, Nevada

  • ALLCUTIS Research, LLC.

    Portsmouth, New Hampshire

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.